Pharming Group (NASDAQ:PHAR) Shares Up 5.4% – Should You Buy?

Pharming Group (NASDAQ:PHARGet Free Report)’s share price shot up 5.4% during mid-day trading on Tuesday . The stock traded as high as $9.25 and last traded at $9.59. 2,252 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 5,358 shares. The stock had previously closed at $9.10.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on PHAR shares. HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Tuesday, December 17th. Oppenheimer decreased their price objective on Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Finally, Jefferies Financial Group began coverage on shares of Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 price target for the company.

View Our Latest Stock Analysis on PHAR

Pharming Group Stock Up 5.8 %

The stock has a market capitalization of $645.67 million, a PE ratio of -36.61 and a beta of -0.08. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The business has a 50 day moving average of $9.02 and a two-hundred day moving average of $8.43.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in Pharming Group (NASDAQ:PHARFree Report) by 75.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 as of its most recent filing with the Securities & Exchange Commission. 0.03% of the stock is owned by hedge funds and other institutional investors.

About Pharming Group

(Get Free Report)

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Featured Articles

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.